Ocugen (OCGN) Q3 2024 earnings summary

Executive summary

• Advanced gene and cell therapy pipeline, including OCU400 Phase 3 trial for retinitis pigmentosa with FDA and Health Canada approvals and expanded access program; OCU410, OCU410ST, and OCU200 progressing in clinical trials; NeoCart and inhaled vaccine platform also in development.

• OCU400 Phase 3 enrollment expected to complete in H1 2025, with BLA and MAA filings in H1 2026 and commercialization targeted for 2027.

• OCU410 and OCU410ST progressing in Phase 1/2 trials for geographic atrophy and Stargardt disease, with preliminary safety and efficacy data to be presented in November 2024.

• OCU200 received FDA clearance for Phase 1 trial in diabetic macular edema, with initiation planned for Q4 2024.

• Recent $30M debt and $35M equity financings, along with July 2024 public offering, extend cash runway into Q1 2026.

Financial highlights

• Cash and restricted cash totaled $39M as of September 30, 2024, compared to $39.5M at year-end 2023.

• Q3 2024 operating expenses were $14.4M, down from $16.1M in Q3 2023; R&D expenses were $8.1M and G&A expenses were $6.3M.

• Q3 2024 net loss was $13.0M, compared to $11.7M in Q3 2023; net loss per share was $(0.05).

• Q3 2024 revenue was $1.1M, down from $3.7M in Q3 2023.

• Accumulated deficit at September 30, 2024, was $326.3M.

Outlook and guidance

• Cash runway projected to extend into Q1 2026 following recent financings.

• OCU400 Phase 3 trial enrollment expected to complete in H1 2025; BLA and MAA filings planned for H1 2026; commercialization targeted for 2027.

• OCU410 and OCU410ST dosing to complete in early 2025, with preliminary data to be presented in November 2024.

• OCU200 Phase 1 trial initiation planned for Q4 2024.

• Management is pursuing additional capital through equity, debt, partnerships, and government funding.